ImmuneXcite is a biopharmaceutical company focused on developing the next generation of monoclonal antibodies for cancer, employing a unique immunotherapy platform
Neutrophils attracted to unique fungal carbohydrate
Neutrophils attracted to unique fungal carbohydrate
Fungal carbohydrate is conjugated to cancer-targeting monoclonal antibodies
Fungal carbohydrate is conjugated to cancer-targeting monoclonal antibodies
Tumor cells recognized by mAbXcite antibodies
Tumor cells recognized by mAbXcite antibodies
Neutrophils attracted to mAbXcite antibodies
Neutrophils attracted to mAbXcite antibodies
Neutrophils lead to destruction of tumor cells
Neutrophils lead to destruction of tumor cells

Read About Our Technology >